FENDRR reduces tumor invasiveness in prostate cancer PC-3 cells by targeting CSNK1E.
CONCLUSIONS: These results suggest that FENDRR in prostate cancer may reduce tumor invasion in prostate cancer PC-3 cells by targeting CSNK1E, which may have favourable effort to better understand the underlying pathogenesis of prostate cancer and provide a tough theoretical basis for further studying prostate cancer.
PMID: 31539119 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
More News: Cancer | Cancer & Oncology | China Health | Drugs & Pharmacology | Genetics | Prostate Cancer | Study | Urology & Nephrology